Last updated: 11/03/2018 20:03:51

Safety and Tolerability of Trametinib in Combination with Docetaxel in Japanese Subjects with Non-small Cell Lung Cancer

GSK study ID
117132
Clinicaltrials.gov ID
NCT01938456
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Other
Other
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: An Open-Label, Phase Ib Study to Assess the Safety and Tolerability of GSK1120212 in Combination with Docetaxel in Japanese Subjects with Non-small Cell Lung Cancer
Trial description: The primary purpose of this study is to evaluate the safety and tolerability of the combination therapy of trametinib and docetaxel with growth factor support in Japanese subjects with Stage IV or a postoperative recurrence non-small cell lung cancer (NSCLC). This study data will be used for making decision for further Japanese development plan for NSCLC. Six evaluable subjects will be enrolled in a dose level to evaluate the safety and tolerability of the combination treatment. Dose-limiting toxicity will be assessed during the first 21 days of combination therapy.
Primary purpose:
Treatment
Trial design:
Single Group Assignment
Masking:
None (Open Label)
Allocation:
Non-randomized
Primary outcomes:

Change from baseline in laboratory parameter values.

Timeframe: Baseline and up to 6 months

Change from baseline in vital sign values

Timeframe: Baseline and up to 6 months

Number of participants with Adverse events (AEs).

Timeframe: Baseline and up to 6 months

Secondary outcomes:

Composite of pharmacokinetic (PK) parameters for

Timeframe: PK samples will be collected at pre-dose, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 10, 24 hours (pre-dose) post-dose/infusion start

Composite of PK parameters for Docetaxel

Timeframe: PK samples will be collected at pre-dose, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 10, 24 hours (pre-dose) post-dose/infusion start

Tumor response as defined by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1

Timeframe: 6 months

Interventions:
  • Drug: Trametinib
  • Drug: Docetaxel
  • Drug: Filgrastim
    • Enrollment:
    0
    Primary completion date:
    Not applicable
    Observational study model:
    Not applicable
    Time perspective:
    Not applicable
    Clinical publications:
    Not applicable
    Medical condition
    Lung Cancer, Non-Small Cell
    Product
    trametinib
    Collaborators
    Not applicable
    Study date(s)
    October 2013 to May 2014
    Type
    Interventional
    Phase
    1

    Participation criteria

    Sex
    Female & Male
    Age
    20+ years
    Accepts healthy volunteers
    No
    • Inclusion Criteria
    • Subjects eligible for enrolment in the study must meet all of the following criteria:
    Inclusion and exclusion criteria
    Inclusion criteria:
    • Inclusion Criteria Subjects eligible for enrolment in the study must meet all of the following criteria:
    • Provided signed written informed consent.
    • 20 years old or older (at the time consent is obtained).
    • Histologically or cytologically confirmed NSCLC.
    • Diagnosed of Stage IV, or postoperative recurrence.
    • Tumor progression after receiving one prior platinum-based chemotherapy. Targeted therapies (gefitinib, crizotinib, etc) with no significant hematological toxicities will not be counted.
    • Performance status score of ≤1 according to the Eastern Cooperative Oncology Group (ECOG) scale.
    • Able to swallow and retain orally administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels.
    • All prior treatment-related toxicities must be CTCAE v4.0 <=Grade 1 (except alopecia) at the time of enrollment.
    • Women of childbearing potential must have a negative serum pregnancy test within 7 days of the first dose of study treatment and agree to use effective contraception throughout the treatment period, and for 4 months after the last dose of study treatment.
    • Men must agree to use effective contraception throughout the treatment period of docetaxel.
    • Adequate organ baseline function defined as Hematology: absolute neutrophil count>=1.5 x 10^9/Liter (L), hemoglobine>=9 gramms/decilitre, platelet>==100 x 10^9/L, Prothrombine time/international normalized ratio and activated partial thromboplastine time<=1.5 x upper limit of normal (ULN) Hepatic: albumin>=2.5 grams/decilitre, total bilirubine <=ULN, aspartate aminotransferase and alanine aminotransferase <=1.5 x ULN if alkaline phosphatase is >=ULN or <=2.5 ULN if alkaline phosphatase is =50 millilter (mL)/minute. Cardiac:left ventricular ejector factor>=lower limit of normal by echocardiogram.
    • Negative for Hepatitis B surface (HBs) antigen, Hepatitis virus B core (HBc) antibody, HBs antibody and Hepatitis C Virus (HCV) antibody. If HBs antigen is negative and both or either of HBc and HBs antibody is positive, Hepatitis B Virus (HBV) DNA should be measured. Exclusion Criteria
    • Anti-cancer therapy (including chemotherapy, radiation therapy, immunotherapy, biologic therapy, hormonal therapy, major surgery, tumor embolization or investigational therapy) within the last three weeks, with the following exceptions: six weeks for prior nitrosourea or mitomycin C and two weeks for anti-cancer therapy given continuously or on a weekly basis with limited potential for delayed toxicity.
    • Previously treated with docetaxel
    • Previously treated with MEK inhibitor
    • Current use of a prohibited medication
    • Suspected of or currently have clinically significant infectious disease.
    • Hypersensitivity to polysorbate 80.
    • Hypersensitivity to filgrastim or growth factor
    • History or current evidence/risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR): History of RVO or CSR, or predisposing factors to RVO or CSR (e.g., uncontrolled glaucoma or ocular hypertension, uncontrolled systemic disease such as hypertension, diabetes mellitus, or history of hyperviscosity or hypercoagulability syndromes) Visible retinal pathology as assessed by ophthalmologic exam that is considered a risk factor for RVO or CSR such as: Evidence of new optic disc cupping, Evidence of new visual field defects on automated perimetry, Intraocular pressure >21 millimeter of mercury (mmHg) as measured by tonography.
    • Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression. Subjects who require treatment for these conditions should be excluded.
    • History of another malignancy. Exception: Subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or in situ carcinoma are eligible.
    • Any serious and/or unstable pre-existing medical (aside from malignancy exception above), psychiatric disorder, or other conditions that could interfere with subject’s safety, obtaining informed consent or compliance to the study procedures.
    • History of interstitial lung disease or pneumonitis
    • Evidence of severe or uncontrolled systemic diseases (e.g., unstable or uncompensated respiratory, hepatic, renal, metabolic, or cardiac disease).
    • History or evidence of cardiovascular risk including any of the following: LVEF=480 millisecond. History or evidence of current clinically significant uncontrolled arrhythmias. Exception: Subjects with controlled atrial fibrillation for >30 days prior to study treatment are eligible. Currently treated subject should be excluded. History of acute coronary syndromes (including myocardial infarction and angina), coronary angioplasty, or stenting within 6 months prior to randomization. Subjects currently treated with anticoagulant. History or evidence of current >= Class II congestive heart failure as defined by New York Heart Association. Treatment refractory hypertension defined as a blood pressure of systolic > 140 mmHg and/or diastolic > 90 mmHg which cannot be controlled by anti-hypertensive therapy. Subjects with intra-cardiac defibrillators or permanent pacemakers. Known cardiac metastases.
    • Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to dimethyl sulfoxide (DMSO).
    • Lactating female
    • Known Human Immunodeficiency Virus (HIV) infection

    Trial location(s)

    This study does not involve prospective enrollment of participants.

    Study documents

    No study documents available.

    Results overview

    Study Results yet to be posted

    Recruitment status
    Other
    Actual primary completion date
    Not applicable
    Actual study completion date
    Not applicable

    Plain language summaries

    Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

    Additional information about the trial

    Additional information
    Not applicable
    Participate in clinical trial
    Access to clinical trial data by researchers
    Visit website